FDA Inspection 1169690 — Carter BloodCare At Grand Prairie
The FDA completed an inspection of Carter BloodCare At Grand Prairie on May 11, 2022 in Grand Prairie, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 11, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Grand Prairie, TX (United States)